Epizyme, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Net loss
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation
Amortization of discount (premium) on investments
Amortization of debt discount
Change in fair value of warrant liability
Loss on disposal of property and equipment
Non-cash royalty revenue related to sale of future royalties
Non-cash interest expense associated with the sale of future royalties
Deferred income taxes
Changes in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other current assets
Accounts payable
Accrued expenses
Deferred revenue
Other assets
Other long-term liabilities
Operating lease assets
Operating lease liabilities
Other assets and liabilities

Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of available-for-sale securities
Maturities of available-for-sale securities
Purchase of intangible asset
Purchases of property and equipment
Net cash provided by (used in) investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of commissions
Proceeds from issuance of preferred stock, net of commissions
Payment of offering costs
Proceeds from the issuance of debt
Proceeds from the issuance of warrants
Payment of debt issuance costs
Proceeds from the issuance of common stock, warrants, and sale of future royalties to RPI, net of offering costs
Proceeds from the issuance of common stock in connection with the exercise of the Put Option, net of financing costs
Payment under capital lease obligation
Proceeds from stock options exercised
Issuance of shares under employee stock purchase plan
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents, and restricted cash, beginning of period
Cash, cash equivalents, and restricted cash, end of period
SUPPLEMENTAL CASH FLOW INFORMATION:
Unpaid offering costs
Unpaid debt issuance costs
Cumulative adjustment related to the adoption
ASU 2016-09
Total cumulative adjustment related to the adoption
Interest paid
Property and equipment included in accounts payable or accruals
Cash paid for income taxes

Comments